As filed with the U.S. Securities and Exchange Commission on January 28, 2026 Registration No. 333-292789 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 8900 85-4359258 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identif ...

As filed with the U.S. Securities and Exchange Commission on January 16, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) | Nevada | 8900 | 85-4359258 | | --- | --- | --- | | (State or jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code ...

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

As filed with the U.S. Securities and Exchange Commission on December 5, 2025 Registration No. 333-290722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 8900 85-4359258 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identif ...

Core Viewpoint - Zacks Investment Research has initiated coverage of Inspire Veterinary Partners Inc. (IVP) with an Underperform rating due to ongoing financial challenges and structural issues that may hinder shareholder returns in the near to medium term [1] Financial Performance - Inspire Veterinary reported year-to-date net losses of $8 million and an accumulated deficit of $44.3 million as of Q3 2025, raising concerns about its viability as a going concern [2] - The company has negative working capital of $5.9 million and relies on high-cost external financing, with some interest rates exceeding 50% [3] - Revenue declined to $12.2 million in the first nine months of 2025 from $13.3 million in the same period in 2024, indicating that its acquisition-led growth model is not yet yielding consistent revenue growth [4] - The company recorded a negative operating cash flow of $3.6 million in the first nine months of 2025, continuing a trend of cash burn that necessitates ongoing external funding [5] Growth Strategy - Inspire Veterinary aims to expand to 50 hospitals by 2029 and reach $40 million in annual revenues by 2027, with plans to launch an online pet pharmacy in early 2026 to create a new high-margin revenue stream [6] - The company secured up to $10 million in new financing through a convertible preferred offering in August 2025, which enhances near-term liquidity and supports acquisitions [7] - Management targets cash flow breakeven by mid-2026, focusing on improved clinic-level efficiencies and cost control initiatives [7] Market Sentiment - Shares of Inspire Veterinary have significantly declined this year, reflecting investor concerns regarding the company's financial trajectory and strategic execution [8] - The stock trades at levels indicating low market confidence in the company's ability to achieve sustainable growth or profitability in the near term [8] Industry Context - Despite operating in a growing U.S. veterinary services market, Inspire Veterinary faces substantial financial and operational challenges, including reliance on external funding, ongoing losses, and shareholder dilution [9]

Core Insights - Several companies have emerged as significant losers in the market, experiencing notable price drops and volatility [1][7] Company Summaries - **OneConstruction Group Limited (ONEG)**: The company's stock price fell to $2.35, a decrease of 54.18%. Revenue decreased by 16.2% to $53.2 million for the fiscal year ending March 31, 2025, raising concerns about market sentiment and operational challenges [2][8] - **SCHMID Group N.V. Warrants (SHMDW)**: The stock price decreased by 53.97% to $0.41. The decline from a year-high of $0.9651 to a low of $0.36 may reflect market reactions to company performance or broader industry trends [3][8] - **Taitron Components Incorporated (TAIT)**: The stock price dropped to $1.12, a 46.56% decrease. Despite this, the company declared a quarterly cash dividend of $0.035 per share, aiming for an annual dividend of $0.14 per share. The decline from a high of $5.1 to a low of $1.11 may be influenced by operational challenges or shifts in demand within the technology sector [4][8] - **Inspire Veterinary Partners, Inc. (IVP)**: The company's stock price decreased by 39.99% to $0.46. However, it reported a 7% increase in total revenues to $4.3 million and a 27% reduction in net losses for the third quarter of 2025. The downturn from a high of $6.3 to a low of $0.419 could be attributed to market sentiment or competitive pressures [5][8] - **Republic Power Group Limited Class A Ordinary Shares (RPGL)**: The stock price fell to $0.51, a 38.97% drop. The company closed its initial public offering on October 15, 2025, with shares priced at $4.00 each. The decline from a year-high of $5.19 to a low of $0.4551 suggests challenges that may include market competition or operational hurdles [6][8]

Core Insights - Inspire Veterinary Partners, Inc. reported a total revenue of $4.3 million for Q3 2025, reflecting a 7% increase compared to the same period last year and a 1% sequential increase from Q2 2025 [1] Financial Performance - Total revenues increased by 7% compared to the prior year period [1] - Net losses decreased by 27% compared to the prior year period [1] - Comparable clinic revenues increased by 9.2% versus the prior year period [1]

Company Operations and Growth Strategy - Inspire Veterinary Partners, Inc. operates 14 clinics across 9 states, focusing on small animal general practice and expanding into equine care and emergency services[201][206] - The company has acquired multiple veterinary practices, with transaction values ranging from $500,000 to $3,108,652, totaling significant investments in growth[213] - Future growth strategies include entering emergency care and mixed animal services, with a focus on acquiring multi-unit practices to enhance market presence[207][211] - The company plans to continue acquiring existing general practice and specialty hospitals, aiming for a mix of 2 to 6 hospitals in clusters to accelerate growth[211] - The company has developed metrics for assessing and integrating new hospitals, focusing on markets with large pet populations[206] Financial Performance - The Company reported total revenue of $12,238,875 for the nine months ended September 30, 2025, a decrease of 8% from $13,270,973 in 2024[230] - Service revenue decreased by 7% to $9,074,965, while product revenue fell by 11% to $3,163,910[231] - The net loss attributable to Class A and B common stockholders was $7,975,878 for the nine months ended September 30, 2025, compared to a loss of $10,518,389 in 2024[230] - Average Daily Service Revenue decreased to $31,979, down from $35,531 in the previous year, reflecting a decline of $3,552[231] - Net loss decreased by $2,321,661 or 23%, to $7,975,878 for the nine months ended September 30, 2025, compared to $10,297,539 for the same period in 2024[246] Acquisitions and Financing - The acquisition of Kauai Veterinary Clinic resulted in a gain of $467,049 in fiscal year 2024, recorded as "Gain on sale of business" in the Statements of Operations[215] - The total transaction value for the acquisition of Kauai Veterinary Clinic and its real estate was $2,805,000, financed through loans[214] - The Company acquired Dietz Family Pet Hospital for $500,000, financed by a loan of $382,500 from WealthSouth[222] - The acquisition of Aberdeen Veterinary Clinic was completed for $574,683, with financing of $445,981 from WealthSouth[223] - The Pony Express Veterinary Hospital acquisition cost $2,608,652, with an additional $500,000 for real estate, financed by loans totaling $2,853,314[225] Risks and Challenges - Staffing shortages and rising acquisition costs pose risks to the company's ability to integrate new hospitals effectively[208][209] - The company expects to incur additional costs and require additional capital as it continues to acquire veterinary hospitals, clinics, and practices[261] - The company has experienced recurring losses and had negative working capital of $5,894,301 as of September 30, 2025[264] Debt and Capital Structure - The company entered into a master line of credit loan agreement providing for a $2,000,000 revolving secured credit facility and an $8,000,000 closed-end line of credit[268] - A total of $7,623,235 in commercial loans was reported, with $2,961,673 due by September 30, 2025, and $3,361,618 due by December 31, 2024[283] - The company recorded a beneficial conversion feature of $1,569,395 based on the IPO price of $40 per share for the Convertible Debentures converted into common stock[288] - The company has a long-term portion of notes payable amounting to $8,254,408 as of September 30, 2025[286] - The Company reported total notes payable of $11,760,153 as of September 30, 2025, with unamortized debt issuance costs of $81,146[286] Cash Flow and Operating Activities - Cash used in operations was $3,598,738 during the nine months ended September 30, 2025[260] - For the nine months ended September 30, 2025, net cash used in operating activities was $3,555,276, a significant improvement from $9,328,339 in the same period of 2024[314] - The Company provided $5,334,147 in net cash from financing activities for the nine months ended September 30, 2025, compared to $10,036,732 in 2024[314] Customer Retention and Valuation - The annual sales retention rate for the customer base was reported at 74.0%, which is consistent with the Veterinary Services industry rate[329] - An increase in the retention rate by 6% to 80% would result in an increase of approximately $1.2 million to the client list and a decrease of approximately $1.2 million to goodwill[330] - The company utilized a discount rate of 19.6% to calculate the present value of prospective after-tax cash flows associated with the customer base[329] Economic Factors - The company does not believe inflation has had a material effect on its business, financial condition, or results of operations[336] - The company has not used any financial instruments to hedge potential fluctuations in interest rates, which could impact the valuation and profitability of acquired hospitals[335]

Core Insights - Inspire Veterinary Partners, Inc. is launching an online pet pharmacy to provide high-quality prescription and over-the-counter products for pet health starting in Q1 2026 [1] Company Overview - Inspire Veterinary Partners, Inc. operates as a provider of pet health care services across the U.S. [1] Industry Context - The online pharmacy aims to leverage extensive relationships within the veterinary medicine industry to enhance access to pet healthcare products [1]

Core Insights - Inspire Veterinary Partners, Inc. is experiencing positive client growth and momentum compared to previous years [1] - The company is positioned for success and has returned to a growth trajectory [1] Company Achievements - Inspire Veterinary Partners has highlighted key achievements that demonstrate progress year to date [1] - The leadership, including Chairman and CEO Kimball Carr, emphasizes the company's improved positioning for future success [1]